Melphalan: A potential new agent in the treatment of childhood rhabdomyosarcoma

J. A. Houghton, R. L. Cook, P. J. Lutz, Peter J Houghton

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Melphalan has been evaluated against a series of seven childhood rhabdomyosarcomas, each derived from a different patient and maintained in vivo as xenografts in immune-deprived mice. Six lines were derived from untreated tumors and one from a patient refractory to conventional therapy. At the maximum tolerated dose (LD10) a single administration of melphalan caused complete regressions of advanced tumor in six of seven lines, including xenografts derived from the refractory patient. This agent demonstrated activity over a broad range of doses, and was considerably more active than vincristine, cyclophosphamide, doxorubicin, and dactinomycin in the model.

Original languageEnglish (US)
Pages (from-to)91-96
Number of pages6
JournalCancer Treatment Reports
Volume69
Issue number1
StatePublished - Jan 1 1985
Externally publishedYes

Fingerprint

Melphalan
Rhabdomyosarcoma
Heterografts
Maximum Tolerated Dose
Dactinomycin
Vincristine
Doxorubicin
Cyclophosphamide
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Melphalan : A potential new agent in the treatment of childhood rhabdomyosarcoma. / Houghton, J. A.; Cook, R. L.; Lutz, P. J.; Houghton, Peter J.

In: Cancer Treatment Reports, Vol. 69, No. 1, 01.01.1985, p. 91-96.

Research output: Contribution to journalArticle

Houghton, J. A. ; Cook, R. L. ; Lutz, P. J. ; Houghton, Peter J. / Melphalan : A potential new agent in the treatment of childhood rhabdomyosarcoma. In: Cancer Treatment Reports. 1985 ; Vol. 69, No. 1. pp. 91-96.
@article{2250d343a5ea4c679180c5fb07052a04,
title = "Melphalan: A potential new agent in the treatment of childhood rhabdomyosarcoma",
abstract = "Melphalan has been evaluated against a series of seven childhood rhabdomyosarcomas, each derived from a different patient and maintained in vivo as xenografts in immune-deprived mice. Six lines were derived from untreated tumors and one from a patient refractory to conventional therapy. At the maximum tolerated dose (LD10) a single administration of melphalan caused complete regressions of advanced tumor in six of seven lines, including xenografts derived from the refractory patient. This agent demonstrated activity over a broad range of doses, and was considerably more active than vincristine, cyclophosphamide, doxorubicin, and dactinomycin in the model.",
author = "Houghton, {J. A.} and Cook, {R. L.} and Lutz, {P. J.} and Houghton, {Peter J}",
year = "1985",
month = "1",
day = "1",
language = "English (US)",
volume = "69",
pages = "91--96",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Melphalan

T2 - A potential new agent in the treatment of childhood rhabdomyosarcoma

AU - Houghton, J. A.

AU - Cook, R. L.

AU - Lutz, P. J.

AU - Houghton, Peter J

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Melphalan has been evaluated against a series of seven childhood rhabdomyosarcomas, each derived from a different patient and maintained in vivo as xenografts in immune-deprived mice. Six lines were derived from untreated tumors and one from a patient refractory to conventional therapy. At the maximum tolerated dose (LD10) a single administration of melphalan caused complete regressions of advanced tumor in six of seven lines, including xenografts derived from the refractory patient. This agent demonstrated activity over a broad range of doses, and was considerably more active than vincristine, cyclophosphamide, doxorubicin, and dactinomycin in the model.

AB - Melphalan has been evaluated against a series of seven childhood rhabdomyosarcomas, each derived from a different patient and maintained in vivo as xenografts in immune-deprived mice. Six lines were derived from untreated tumors and one from a patient refractory to conventional therapy. At the maximum tolerated dose (LD10) a single administration of melphalan caused complete regressions of advanced tumor in six of seven lines, including xenografts derived from the refractory patient. This agent demonstrated activity over a broad range of doses, and was considerably more active than vincristine, cyclophosphamide, doxorubicin, and dactinomycin in the model.

UR - http://www.scopus.com/inward/record.url?scp=0021934470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021934470&partnerID=8YFLogxK

M3 - Article

C2 - 3967262

AN - SCOPUS:0021934470

VL - 69

SP - 91

EP - 96

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -